PYC Therapeutics Advances Candidate to Human Trials miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
– Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential for STK-001 as a disease-modifying potential medicine for the treatment.
Stoke Therapeutics late Tuesday disclosed plans to sell up to $75 million of its common shares through a public stock offering, subject to market and other conditions.
The biotechnology company.
Stoke Therapeutics shares were up 68% in recent Tuesday trading, a day after the company reported its investigational new medicine STK-001 was found to benefit subjects with Dravet syndrome, a.
Stoke Therapeutics has an average buy rating and price target range of $13 to $35, according to analysts polled by Capital IQ.
Price: 11.54, Change: +5.04, Percent Change: +77.54
.